Frost & Sullivan Releases the 2026 Blue Book on the Internationalization of China’s Biopharmaceutical Industry
APIs and intermediates: from cost leadership to capability Innovative medicines: multiple routes to global markets M&A and NewCo structures 2 APIs and Intermediates 3 Generic Drugs and Biosimilars Company Name: Frost & Sullivan Contact Person: Qian Li